Friday January 19th 2018

Biogen’s Tecfidera approved in Europe, first launch expected in Germany

Biogen Idec has received approval to launch its soon-to-be blockbuster multiple sclerosis drug, Tecfidera, in Europe, and plans to begin with a launch in Germany in the coming weeks. Approval was widely expected after a committee of the European Medicines Agency voted in favor of the oral pill last November, but the launch was delayed as the Cambridge, Mass.-based company sought 10 extra years of protection there before generic versions of the drug would be allowed. Besides U.S. approval last March,… (Source: bizjournals.com Health Care:Biotechnology headlines)

Read article here: 

Biogen’s Tecfidera approved in Europe, first launch expected in Germany

Leave a Comment

More from category

Researchers unravel key molecular mechanism of autoimmune and inflammatory diseases
Researchers unravel key molecular mechanism of autoimmune and inflammatory diseases

An international team of researchers led by prof. Savvas Savvides has unraveled a crucial aspect of the molecular basis [Read More]

Kessler Foundation wins $735,000 grant for training rehabilitation researchers
Kessler Foundation wins $735,000 grant for training rehabilitation researchers

Guang Yue, PhD, director of Human Performance and Engineering Research at Kessler Foundation, has been awarded a [Read More]

6,000-year-old track record for healing leaky gut
6,000-year-old track record for healing leaky gut

When I was traveling in India, I had the privilege of studying Ayurvedic medicine with traditional Master Healers. [Read More]

Study shows high-salt diet causes dementia in mice
Study shows high-salt diet causes dementia in mice

A high-salt diet reduces resting blood flow to the brain and causes dementia in mice, according to a new study by [Read More]

What you should know about neurosarcoidosis
What you should know about neurosarcoidosis

A look at neurosarcoidosis, an inflammatory disease that can affect most organs in the body. Included is detail on [Read More]